Safety and PK Results From an Ongoing Phase I-II Study of ONA in Patients With PR-Expressing Cancers
July 10th 2015Paul Cottu, MD, MSc, medical oncologist, Institut Curie, Paris, discusses safety and pharmacokinetic (PK) results from phase I of an ongoing phase I-II study of onapristone (ONA) in patients with progesterone receptor (PR)-expressing cancers.
Watch
Effects of SIRT and Bevacizumab on Extrahepatic CRC Metastases
July 9th 2015Guy Van Hazel, MD, Medical Oncologist, Mount Hospital and School of Medicine University of Western Australia, discusses the effects of selective internal radiation therapy (SIRT) and bevacizumab on extrahepatic colorectal cancer (CRC) metastases.
Watch
RAVD of Radiotherapy Using Induction Chemotherapy in LA-HNSCC
July 8th 2015Victoria M. Villaflor, MD, medical oncologist, associate professor, University of Chicago Medicine, discusses response-adapted volume de-escalation (RAVD) of radiotherapy (RT) using induction chemotherapy (IC) in locally advanced head and neck squamous cell cancer (LA-HNSCC).
Watch
Nivolumab Compared to Docetaxel in Patients With NSCLC
July 8th 2015Karen Reckamp, MD, MS, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, Department of Medical Oncology and Therapeutics Research, discusses nivolumab (Opdivo) compared to docetaxel for the treatment of patients with non-small cell lung cancer (NSCLC).
Watch
Impact of a Stage IV NSCLC Care Pathway on Frontline and Maintenance Chemotherapy Use
July 7th 2015James Stevenson, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the impact of a stage IV non-small cell lung cancer (NSCLC) care pathway on frontline and maintenance chemotherapy use.
Watch
Baseline Analysis of CTC Enumeration and AR Localization in Men With mCRPC
July 7th 2015Scott T. Tagawa, MD, MS, medical director, Genitourinary Oncology Research Program, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses the baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC).
Watch
Daratumumab for the Treatment of Patients With Multiple Myeloma
July 6th 2015Peter Voorhees, MD, associate professor, School of Medicine, UNC-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses a phase II study examining daratumumab for the treatment of patients with multiple myeloma.
Watch
Avelumab in Patients With Relapsed or Recurrent Ovarian Cancer
July 2nd 2015Jeffrey Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase Ib, open-label expansion trial examining avelumab for the treatment of patients with previously treated, recurrent or refractory ovarian cancer.
Watch
Palbociclib Combined With Fulvestrant in Relapsed Metastatic HR+/HER2- Breast Cancer
July 1st 2015Shannon Puhalla, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses a phase III study examining the combination of palbociclib and fulvestrant for the treatment of patients with relapsed metastatic hormone receptor-positive, HER2-negative breast cancer.
Watch
Immunotherapy in Prostate Cancer
June 30th 2015Maha H. Hussain, MD, professor of Medicine and Urology, University of Michigan, associate director, Clinical Research, co-leader, Prostate Cancer/GU Oncology Program, assistant chief, Clinical Research at the Division of Hematology/ Oncology, University of Michigan Comprehensive Cancer Center, discusses immunotherapy in prostate cancer.
Watch
Ipilimumab Combined With Nivolumab for the Treatment of Patients With Melanoma
June 30th 2015Anna C. Pavlick, MD, associate professor, co-director, Melanoma Program, assistant director, Clinical Research Education, discusses a study that examined two immunotherapy agents, ipilimumab and nivolumab, in patients with melanoma.
Watch
Pembrolizumab in Urothelial Cancer
June 26th 2015Elizabeth Plimack, MD, MS, attending physician, genitourinary cancer associate professor, Medical Oncology Director of Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a study that examined pembrolizumab in patients with urothelial cancer.
Watch